097 TREATMENT WITH AN AGGRECANASE SPECIFIC INHIBITOR AND LUBRICIN SIGNIFICANTLY REDUCES JOINT PAIN IN A RAT MODEL OF POST-TRAUMATIC ARTHRITIS  by Rivera-Bermudez, M.A. et al.
S50 Poster Presentations / Osteoarthritis and Cartilage 18, Supplement 2 (2010) S45–S256
Figure 2. Patella.
Figure 3. Trochlea.
increased, but its volume was reduced after three weeks of running,
becoming signiﬁcant after 12 weeks (p=0.0007) (Figure 2). Attenuation
was signiﬁcantly increased in trochlear cartilage at 12 weeks (p=0.009),
although not signiﬁcant, trochlear cartilage volume showed a clear trend of
reduction from one to 12 weeks (Figure 3).
Conclusions: With CECT we successfully analyzed OA progression in knee
joints of strenuous running Wistar rats. Our data suggests that 6 weeks of
running damages cartilage beyond the ability for repair, which results in
OA progression even when rats are not forced to run anymore. In addition,
we demonstrate that besides disease progression at the weight-bearing
condyles, the articular cartilage of the femoral bone and the patella is also
affected. Our ﬁndings demonstrate that this model could very well be used
for testing DMOADs, also after the OA inducing running stimulus has been
stopped. In such a study, (regenerative) compounds can be tested without
the stimulus inducing OA and counteracting a possible positive effect of the
studied drug.
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TREATMENT WITH AN AGGRECANASE SPECIFIC INHIBITOR AND LUBRICIN
SIGNIFICANTLY REDUCES JOINT PAIN IN A RAT MODEL OF
POST-TRAUMATIC ARTHRITIS
M.A. Rivera-Bermudez, J. Tejada, T.J. Blanchet, S. Soucy, L. Savary,
K. Georgiadis, C.R. Flannery, S.S. Glasson
Pﬁzer, Cambridge, MA
Purpose: Traumatic joint injuries lead to an increased incidence of acceler-
ated and progressive loss of the normal structure and function of articular
cartilage, resulting in pain and signiﬁcant disability. The rat meniscal tear
(MT) model of post-traumatic arthritis (PTA) is a primary in vivo system for
testing the ability of potential therapeutics to slow cartilage degradation
and pain following acute injury. It has previously been demonstrated that
treatment with either an aggrecanase speciﬁc inhibitor (ASI) or recom-
binant lubricin is chondroprotective in the rat MT model. In the current
study, we evaluated the effect of treatment with ASI and Lubricin, either
dosed separately or in combination, on pain in this model.
Methods: All in vivo experimental procedures were IACUC reviewed and
approved. Male Lewis rats underwent medial MT surgery on the right knee
to induce joint instability. Study #1: rats were dosed with vehicle, 60
mg/kg/day ASI (PO, starting on the day of surgery), 20 μg of intra-articular
(IA) recombinant lubricin (LUB1; 3X/week, starting one week post-surgery)
or combined dosing with both ASI and LUB1. Dosing was terminated
5 weeks post-surgery. Study #2 replicate the dosing paradigm in study
1, but at 5 weeks post-surgery, dosing ceased and the study continued
for an additional 5 weeks. The change in hind paw weight distribution
between the ipsilateral knee and contra-lateral knee was measured with
an incapacitance meter (Linton, CO) at various time points.
Results: Treatment with ASI and LUB1 signiﬁcantly reduced pain 4 weeks
after surgery. Moreover, combination therapy of ASI and LUB1 proved more
eﬃcacious than either therapy alone. Both ASI and LUB1 continued to
ameliorate pain at 2 and 3 weeks after dose cessation.
Conclusions: The present study demonstrates that ASI and LUB1, both
separately, and to a greater extent in combination, have the potential to
signiﬁcantly reduce joint injury-associated pain during the progression of
PTA. Treatment with ASI and LUB1 alone also proved eﬃcacious in reducing
pain 3 weeks after dose termination, suggesting that the effect on pain
can be prolonged for a substantial period after ASI and LUB1 treatment
cessation. These results support the development of ASI and LUB1 as
potential therapies following joint injuries in humans, to provide both pain
relief as well as chondroprotection.
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USE OF GAIT ANALYSIS AS AMEASURE OF SPONTANEOUS PAIN BEHAVIOR
IN MURINEMODELS OF ARTHRITIS
C. Dorman1, H.E. Krug2,1, S.R. Anderson2, S.V. Frizelle1, M.L. Mahowald2,1
1VA Med. Ctr., Minneapolis, MN; 2Univ. of Minnesota, Minneapolis, MN
Purpose: Murine models of arthritis are important tools for the study of
arthritis pain and discovery of new analgesic therapies, however measuring
pain in mice can be challenging. We have previously described sensitive
and speciﬁc methods for measuring evoked pain behaviors in mice with
acute and chronic arthritis pain. But it is also desirable to incorporate the
measurement of spontaneous behaviors that are sensitive to change with
pain and analgesia. We have used two methods of digitized gait analysis to
detect changes in spontaneous gait behavior in order to quantify pain in
murine models of arthritis and to detect analgesic responses.
Methods: C57Bl6 mice were used for all experiments. In all cases arthritis
was produced only in the left knee. Chronic arthritis was produced by IA
injection of 10 IU Collagenase. Acute inﬂammatory arthritis was produced
by IA injection of 10 μl 3% carrageenan. Analgesia was provided by
Botulinum toxin type A (BoNT/A) (0.02 IU) which was given IA into the
left knee 3 days before testing. The normal right knee served as internal
nonpainful control. Mice were studied in the naïve pre-arthritic state, after
induction of arthritis and after IA BoNT/A or saline control treatment.
Video gait analysis was performed using DigiGait™ (Mouse Speciﬁcs, Inc,
Quincy, MA) hardware and software and TreadScan digitized gait analysis
system (Clever Sys, Inc. Reston, VA) Evoked pain behavior was measured by
tallying ﬁghts + vocalizations/1 min in response to repeated ﬁrm palpation
of the knee preformed by a single, trained examiner. Strength was observed
visually and graded semiquantitatively as ability to grasp and cling to
a wire grid. Visual assessment of gait was also performed and similarly
graded. Student’s t-test was used for statistical comparisons.
Results: No mouse appeared weak as a result of BoNT/A injection. Arthritis
pain was clearly and reproducibly indicated by increased Evoked pain
scores in both acute inﬂammatory and chronic noninﬂammatory arthritic
mice. Analgesia after BoNT/A injection was modest in acute inﬂammatory
arthritis and did not reach statistical signiﬁcance. Anagesia after BoNT/A
was statistically signiﬁcant in mice with chronic arthritis as measured by
Evoked pain scores. Although gross abnormalities of gait could be seen by
visual observation in arthritic mice, speciﬁc alterations in gait parameters
were less common, of small magnitude, and somewhat inconsistent. Similar
results were obtained using two different gait analysis systems. As might
be expected in a quadruped, alterations in gait due to pain did not appear
to be conﬁned to the arthritic limb, but these results were not consistent.
Evoked Pain Response - Left Knee
Mean (SEM) Non-Arthritic Arthritic BoNT/A Rx Saline Rx
Chronic Non-Inﬂammatory Arthritis 2.0 (0.76) 8.2 (1.22) 4.5 (1.04) 8.2 (2.39)
Acute Inﬂammatory Arthritis 1.3 (0.49) 12.8 (3.41) 6.1 (1.21) 10.0 (2.69)
Conclusions: Pain can be quantitated in murine models of arthritis using
visual and computerized gait analysis, and evoked pain scores. Evoked
pain responses increased signiﬁcantly with arthritis and decreased with IA
BoNT/A and appear to be reliable and reproducible. No limb weakness was
noted. Although gross changes in gait can be seen in animals with arthritis,
detection by digitized gait analysis is subject to individual variation, and
